WO2000054813A3 - Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil - Google Patents

Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil Download PDF

Info

Publication number
WO2000054813A3
WO2000054813A3 PCT/US2000/007062 US0007062W WO0054813A3 WO 2000054813 A3 WO2000054813 A3 WO 2000054813A3 US 0007062 W US0007062 W US 0007062W WO 0054813 A3 WO0054813 A3 WO 0054813A3
Authority
WO
WIPO (PCT)
Prior art keywords
eye
treating
gene delivery
preventing diseases
recombinant gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/007062
Other languages
English (en)
Other versions
WO2000054813A2 (fr
Inventor
William C Manning Jr
Varavani J Dwarki
Katherine Rendahl
Shang-Zhen Zhou
Laura H Mcgee
Dana Lau
John G Flannery
Sheldon Miller
Fei Wang
Polo Adriana Di
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
University of California Berkeley
University of California San Diego UCSD
Original Assignee
Chiron Corp
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, University of California Berkeley, University of California San Diego UCSD filed Critical Chiron Corp
Priority to AU37559/00A priority Critical patent/AU3755900A/en
Priority to CA002367375A priority patent/CA2367375A1/fr
Priority to EP00916458A priority patent/EP1183051A2/fr
Priority to JP2000604885A priority patent/JP2002539176A/ja
Publication of WO2000054813A2 publication Critical patent/WO2000054813A2/fr
Publication of WO2000054813A3 publication Critical patent/WO2000054813A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des vecteurs d'administration de gènes, tels que, par exemple, des vecteurs de virus associés aux adénovirus recombinants, ainsi que des techniques d'utilisation de tels vecteurs pour le traitement ou la prévention des maladies de l'oeil.
PCT/US2000/007062 1999-03-15 2000-03-15 Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil Ceased WO2000054813A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU37559/00A AU3755900A (en) 1999-03-15 2000-03-15 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
CA002367375A CA2367375A1 (fr) 1999-03-15 2000-03-15 Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prevention des maladies de l'oeil
EP00916458A EP1183051A2 (fr) 1999-03-15 2000-03-15 Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la pr vention des maladies de l'oeil
JP2000604885A JP2002539176A (ja) 1999-03-15 2000-03-15 眼の疾患を処置または予防するための組換え遺伝子送達ベクターの使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12446099P 1999-03-15 1999-03-15
US60/124,460 1999-03-15
US17498400P 2000-01-06 2000-01-06
US60/174,984 2000-01-06

Publications (2)

Publication Number Publication Date
WO2000054813A2 WO2000054813A2 (fr) 2000-09-21
WO2000054813A3 true WO2000054813A3 (fr) 2001-05-03

Family

ID=26822618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007062 Ceased WO2000054813A2 (fr) 1999-03-15 2000-03-15 Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil

Country Status (5)

Country Link
EP (1) EP1183051A2 (fr)
JP (1) JP2002539176A (fr)
AU (1) AU3755900A (fr)
CA (1) CA2367375A1 (fr)
WO (1) WO2000054813A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531321B2 (en) 2000-03-13 2009-05-12 Amgen Inc Fibroblast growth factor-like molecules and uses thereof
US9284378B2 (en) 2009-12-07 2016-03-15 Shaw-Fen Sylvia Hu Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
JP2002542805A (ja) 1999-04-30 2002-12-17 ユニバーシティ オブ フロリダ アデノ随伴ウイルス送達リボザイム組成物および使用方法
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US7056885B1 (en) 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU2008201780B2 (en) * 1999-09-07 2012-05-17 Amgen Inc. Fibroblast growth factor-like polypeptides
US6797695B1 (en) 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
WO2001031008A2 (fr) * 1999-10-22 2001-05-03 Chiron Corporation Gene fgf-20 humain et produits d'expression genique
WO2001036640A2 (fr) * 1999-11-18 2001-05-25 Chiron Corporation Gene humain fgf-21 et produits d'expression genique
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU780634C (en) * 2000-02-11 2006-02-23 Genvec, Inc. Gene Therapy for treating ocular-related disorders
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
WO2001092522A2 (fr) * 2000-06-01 2001-12-06 Eli Lilly And Company Acides nucleiques et polypeptides humains fgf-20
WO2002002625A2 (fr) * 2000-07-03 2002-01-10 Curagen Corporation Nouveaux facteurs de croissance des fibroblastes et acides nucleiques codant pour ces memes facteurs
WO2002024234A2 (fr) * 2000-09-20 2002-03-28 The Regents Of The University Of California Utilisation de vecteurs recombines d'administration genique pour traiter ou prevenir des maladies de l'oeil
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
US20060094647A1 (en) * 2000-11-06 2006-05-04 Jeffers Michael E Treatment of inflammatory bowel disease using growth factors
PT2301583E (pt) * 2000-12-19 2012-12-06 Res Dev Foundation Transferência de genes mediada por vetor de lentivírus
CA2446285A1 (fr) * 2001-06-15 2002-12-27 Curagen Corporation Facteur de croissance fibroblastique (fgf) et acides nucleiques codant ce facteur
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
NZ535100A (en) * 2002-03-20 2008-04-30 Univ Florida RAAV vector compositions and methods for the treatment of choroidal neovascularization
WO2004027019A2 (fr) 2002-05-01 2004-04-01 University Of Florida Research Foundation, Inc. Systemes d'expression raav ameliores destines a une modification genetique de proteines de capside specifiques
JP2005218780A (ja) * 2004-02-09 2005-08-18 Menicon Co Ltd 薬物放出速度を制御し得る薬物徐放可能なヒドロゲル材料の製造方法
DK2229956T3 (da) 2004-09-13 2013-07-29 Genzyme Corp Multimere konstruktioner
US8648169B2 (en) * 2006-12-05 2014-02-11 The Royal Institution For The Advancement Of Learning/Mcgill University Methods of use of Trk receptor modulators
AU2009212309B2 (en) * 2008-02-07 2014-04-03 Ceregene, Inc. Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein
EP2910637A1 (fr) 2008-05-20 2015-08-26 University of Florida Research Foundation, Inc. Vecteurs pour la délivrance de protéines photosensibles et procédés d'utilisation
EP2296690B1 (fr) 2008-06-04 2016-11-30 Amgen, Inc Mutants fgf21 et leurs utilisations
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
EP2427207B1 (fr) 2009-05-05 2017-08-16 Amgen, Inc Mutants de fgf21 et leurs utilisations
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
CN101947309B (zh) * 2010-04-12 2012-09-19 南海朗肽制药有限公司 人碱性成纤维细胞生长因子滴眼液及其制备方法
CA2796055A1 (fr) 2010-04-15 2011-10-20 Amgen Inc. Proteines de liaison au recepteur de fgf humain et a ?-klotho
PL2601214T3 (pl) 2010-08-06 2018-05-30 Genzyme Corporation Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
AU2015229464B2 (en) 2014-03-11 2021-07-22 Wayne State University A modified mGluR6 promoter and methods of use
KR102537394B1 (ko) 2014-03-17 2023-05-30 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407122A1 (fr) * 1989-07-06 1991-01-09 Repligen Corporation Compositions de PF4 modifié et méthode d'utilisation
WO1995026409A1 (fr) * 1994-03-29 1995-10-05 Rhone-Poulenc Rorer S.A. ADENOVIRUS RECOMBINANTS CODANT POUR LES FACTEURS DE CROISSANCE DES FIBROBLASTES BASIQUES (bFGF)
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
WO1998013071A1 (fr) * 1996-09-24 1998-04-02 Merck & Co., Inc. Therapie genique servant a inhiber l'angiogenese
US5792845A (en) * 1994-04-26 1998-08-11 The Children's Medical Center Corporation Nucleotides encoding angiostatin protein and method of use
WO1998051323A1 (fr) * 1997-05-13 1998-11-19 The Regents Of The University Of California Nouveaux agents peptidiques anti-angiogeniques, utilisation de ces derniers pour la therapie et le diagnostic
WO1999016889A1 (fr) * 1997-10-01 1999-04-08 G.D. Searle & Co. Proteines de fusion comprenant une fraction d'angiostatine et leur utilisation dans un traitement anti-tumeur
JPH11100327A (ja) * 1997-09-26 1999-04-13 Toray Ind Inc 網膜変性症治療剤
WO1999045952A2 (fr) * 1998-03-12 1999-09-16 Genentech, Inc. Methode de prevention de la mort des neurones de la retine et de traitement d'affections oculaires
WO2000001815A2 (fr) * 1998-07-06 2000-01-13 Nsgene A/S Facteurs neurotrophiques
WO2000015822A1 (fr) * 1998-09-17 2000-03-23 University Of Florida Methodes de traitement de maladies degeneratives de la retine

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407122A1 (fr) * 1989-07-06 1991-01-09 Repligen Corporation Compositions de PF4 modifié et méthode d'utilisation
WO1995026409A1 (fr) * 1994-03-29 1995-10-05 Rhone-Poulenc Rorer S.A. ADENOVIRUS RECOMBINANTS CODANT POUR LES FACTEURS DE CROISSANCE DES FIBROBLASTES BASIQUES (bFGF)
US5792845A (en) * 1994-04-26 1998-08-11 The Children's Medical Center Corporation Nucleotides encoding angiostatin protein and method of use
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
WO1998013071A1 (fr) * 1996-09-24 1998-04-02 Merck & Co., Inc. Therapie genique servant a inhiber l'angiogenese
WO1998051323A1 (fr) * 1997-05-13 1998-11-19 The Regents Of The University Of California Nouveaux agents peptidiques anti-angiogeniques, utilisation de ces derniers pour la therapie et le diagnostic
JPH11100327A (ja) * 1997-09-26 1999-04-13 Toray Ind Inc 網膜変性症治療剤
WO1999016889A1 (fr) * 1997-10-01 1999-04-08 G.D. Searle & Co. Proteines de fusion comprenant une fraction d'angiostatine et leur utilisation dans un traitement anti-tumeur
WO1999045952A2 (fr) * 1998-03-12 1999-09-16 Genentech, Inc. Methode de prevention de la mort des neurones de la retine et de traitement d'affections oculaires
WO2000001815A2 (fr) * 1998-07-06 2000-01-13 Nsgene A/S Facteurs neurotrophiques
WO2000015822A1 (fr) * 1998-09-17 2000-03-23 University Of Florida Methodes de traitement de maladies degeneratives de la retine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AKIMOTO ET AL.: "Adenovirally expressed basic fibroblast growth factor rescues photoreceptor cells in RCS rats.", IOVS, vol. 40, February 1999 (1999-02-01), pages 273 - 279, XP000917329 *
CAYOUETTE M ET AL: "ADENOVIRUS-MEDIATED GENE TRANSFER OF CILIARY NEUROTROPHIC FACTOR CAN PREVENT PHOTORECEPTOR DEGENERATION IN THE RETINAL DEGENERATION (RD) MOUSE", HUMAN GENE THERAPY,XX,XX, vol. 8, no. 4, 1 March 1997 (1997-03-01), pages 423 - 430, XP000876513, ISSN: 1043-0342 *
DATABASE WPI Section Ch Week 199925, Derwent World Patents Index; Class B04, AN 1999-296483, XP002156115 *
FOTSIS T. ET AL.: "The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth.", NATURE, vol. 368, 1994, pages 237 - 239, XP002046111 *
LUTHERT ET AL.: "Photoreceptor rescue.", EYE, vol. 12, June 1998 (1998-06-01), London, pages 591 - 596, XP000917332 *
OIKAWA ET AL.: "Three novel synthetic retinoids, RE 80, AM 580 and AM 80, all exhibit anti-angiogenic activity in vivo.", EUROPEAN JOURNAL OF PHARMACOLOGY., vol. 249, 1993, pages 113 - 116, XP000879175 *
PETERSON ET AL.: "Enhanced survival of photoreceptors in p23h mutant rhodopsin transgenic rats by adeno-associated virus (AAV)-madiated delivery of neurotrophic genes.", IOVS, vol. 39, 15 March 1998 (1998-03-15), pages S1117, XP000917442 *
SHAFIEE A. ET AL.: "Thrombospondin peptides inhibit angiogenesis in retinal explant assay and rat model of retinopathy of prematurity.", IOVS, vol. 38, 1997, pages S964, XP000944952 *
SMITH L.E.H. ET AL.: "Inhibition of retinal neovascularization with an IGF-1 receptor antagonist.", IOVS, vol. 39, 1998, pages S450, XP000944951 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531321B2 (en) 2000-03-13 2009-05-12 Amgen Inc Fibroblast growth factor-like molecules and uses thereof
US9284378B2 (en) 2009-12-07 2016-03-15 Shaw-Fen Sylvia Hu Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
US9493577B2 (en) 2009-12-07 2016-11-15 Amgen Inc. Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof

Also Published As

Publication number Publication date
WO2000054813A2 (fr) 2000-09-21
JP2002539176A (ja) 2002-11-19
CA2367375A1 (fr) 2000-09-21
AU3755900A (en) 2000-10-04
EP1183051A2 (fr) 2002-03-06

Similar Documents

Publication Publication Date Title
WO2000054813A3 (fr) Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil
WO2002024234A3 (fr) Utilisation de vecteurs recombines d'administration genique pour traiter ou prevenir des maladies de l'oeil
CZ63995A3 (en) Virus vectors and their use in gene therapy
WO2003011115A3 (fr) Agents de contraste multimères ciblés à base de peptides
WO2002069900A3 (fr) Procede de traitement de troubles proliferatifs d'origine genetique par des inhibiteurs de hsp90
WO2001014424A3 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
WO2001000244A3 (fr) Techniques de traitement utilisant des conjugues maytansinoides-anticorps anti-erbb
WO1996003515A3 (fr) Expression en surface d'une enzyme dans la therapie genique a base de promedicaments
WO1999045098A3 (fr) Apport de proteines a des cellules eucaryotes au moyen de la yersinia recombinee
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
WO1997020933A3 (fr) VARIANTES MUTATIONNELLES DE PROTEINES DE GENES Ob CHEZ LES MAMMIFERES
WO1998048027A3 (fr) Produits agissant contre des affections retiniennes et traitement correspondant
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
WO2000069884A3 (fr) Compositions isolees a partir de cellules cutanees, et leurs procedes d'utilisation
WO2004098536A3 (fr) Activite antivirale de peptides cathelicidiniques
CA2278808A1 (fr) Procedes pour la culture de cellules et la multiplication de virus
WO2003018606A3 (fr) Peptides derives de la caseine et leurs utilisations therapeutiques
WO2006058231A3 (fr) Vecteurs viraux
WO2004019965A3 (fr) Approches tolerogenes a base de thymus destinees au diabete de type i.
WO2004058186A3 (fr) Formulations pour administration pulmonaire
EP0647138A4 (fr) Polypeptides pouvant etre obtenus a partir d'especes de fasciola, et vaccins, procedes de traitement, et sequences d'adn de ces polypeptides.
EP0227604A3 (fr) Emploi d'oligopeptides dans le traitement d'infections virales
WO2001064870A3 (fr) Proteine cycline g1 mutee
AU5295500A (en) Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
AU2002306539A1 (en) Minimal plasmid vectors that provide for persistent and high level gene expression and methods for using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2367375

Country of ref document: CA

Ref country code: CA

Ref document number: 2367375

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 604885

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000916458

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2000916458

Country of ref document: EP

CFP Corrected version of a pamphlet front page

Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWW Wipo information: withdrawn in national office

Ref document number: 2000916458

Country of ref document: EP